13 results about "Myelin sheath structure" patented technology

Compositions and methods for treating, preventing, or reversing neuroinflammation-related disorders or autoimmune neurological disorders in a subject in need thereof are disclosed. The methods comprise administering a therapeutically effective amount of a composition comprising a myelin basic protein (MBP) peptide.

This invention provides methods of detecting biomarkers in the biofluid of sepsis-associated encephalopathy (SAE) patients, including but not limited to glial fibrillary acidic protein (GFAP), ubiquitin C-terminal hydrolase LI, Tan protein, Neurofilament light chain (NF-L), myelin basic protein (MBP), secretogranin, Copeptin, total all-spectrin, all-spectrin breakdown products (SBDP, including SBDP145, SBDP150, SBDP120 all-spectrin N-terminal fragment or SBDP150N), neuron specific enolase (NSE), mature brain derived neurotrophic factor (BDNF), and full-length Pro-BDNF. These biomarker peptides are markers of axonal and blood brain barrier integrity which can be used to diagnose SAE and to assess and predict cognitive performance and outcomes in acute presentations of sepsis.

The present application provides a kind of nutritional composition in the application of the product for improving learning, memory and cognitive ability.The nutritional composition includes animal bifidobacterium lactis subsp.CP-9 and 3'-sialyllactose.Animal bifidobacterium lactis subsp.CP-9 and 3'-sialyllactose can synergistically enhance the memory retention ability of the body, reduce the degree of learning and memory errors, and up-regulate the expression of oligodendrocyte transcription factor 2 coding gene, myelin basic protein coding gene and brain-derived neurotrophic factor coding gene, realize the double regulation of myelin formation and neurotrophic in hippocampus region of brain, synergistically improve the neural plasticity of central nervous system through gut-brain axis pathway, and then double improve the learning, memory and cognitive function of the body from the behavior and molecular level.

The present invention relates to an engineered regulatory T cell (Treg) comprising a T cell receptor (TCR) which is capable of specifically binding to a myelin basic protein (MBP) peptide or variant or fragment thereof when the peptide is presented by a major histocompatibility complex (MHC) molecule. The present invention further relates to methods for providing an engineered Treg and to methods and uses of said engineered Treg and vectors and kits of vectors encoding said Treg.

The invention discloses a method for researching the action mechanism of saikoside D on paclitaxel-induced peripheral neuropathy, and relates to the technical field of disease mechanism research and drug development. Comprising the following steps: performing continuous administration through intraperitoneal injection of paclitaxel, and establishing a paclitaxel-induced peripheral neuropathy animal model; a von Frey cellosilk experiment and a cold and hot plate experiment are adopted for behavioral detection, and mechanical pain threshold and cold and hot pain sense changes are evaluated; the morphological structure change of the sciatic nerve myelin sheath is observed through Luxol Fast Blue staining; and the expression level of the myelin sheath basic protein in the sciatic nerve is detected by using immunofluorescence staining and Western blotting technologies. According to the invention, a closed-loop research system is formed from animal model construction to molecular mechanism verification; based on behavioral detection, histological analysis and multiple dimensions of a molecular biological technology, the data reliability is ensured, and the curative effect of saikoside D can be comprehensively evaluated.

Disclosed is a protein comprising no more than three human autoantigenic proteins, wherein a first human autoantigenic protein comprises a truncated myelin oligodendrocyte glycoprotein (MOG) amino acid sequence, a second human autoantigenic protein comprises a myelin basic protein (MBP) amino acid sequence, and a third human autoantigenic protein comprises a truncated proteolipid protein (PLP) amino acid sequence. Also disclosed are related nucleic acids, pharmaceutical compositions, methods of treating a demyelinating disease, and methods of producing the proteins.

A method of differentiating nonhuman primate induced pluripotent stem cells (iPSCs) to oligodendrocytes is provided. The method may include providing a modified vector comprising a piggyBac vector backbone that expresses one or more differentiation factor genes, including SOX10, OLIG2, and NKX6-2. The piggyBac vector backbone may comprise one or more terminal inverted repeats and one or more transposase recognition sites configured to interact with a piggyBac transposase to mediate genomic integration at TTAA or noncanonical target sequences. The vector may further include a selectable marker and a promoter for regulated expression. The modified vector may be introduced into nonhuman primate iPSCs, for example from Macaca fascicularis, by electroporation and used in a feeder-free differentiation workflow. The resulting differentiated cells may be identified by expression of oligodendrocyte-associated markers including O4, O1, PDGFRA, MOG, GALC, CNPase, and myelin basic protein (MBP).

The application provides an application of 3-(methylsulfonyl) propionitrile in preparation of a medicine for treating peripheral nerve adhesion diseases, relates to the field of biomedical technology, and is verified through a sciatic nerve adhesion mouse model that 3-(methylsulfonyl) propionitrile can effectively reduce the adhesion degree of nerves and peripheral tissues, and can significantly improve muscle atrophy symptoms; compared with the traumatic and high recurrence rate of surgical treatment, the drug is a non-invasive or minimally invasive treatment, has good patient tolerance, can effectively reduce treatment risks and rehabilitation costs, and has wider clinical applicability. Secondly, the drug plays a treatment effect through a double action mechanism: on the one hand, adhesion formation is inhibited, and nerve compression is released; on the other hand, nerve myelin sheath regeneration can be promoted, myelin sheath structure integrity is improved, nerve conduction velocity is improved, and the synergistic effect of 'adhesion release + nerve repair' is realized. Animal experiments prove that the drug can significantly improve the motion balance ability and gait function of model mice.

The invention provides a delay neuron circuit designed based on an FH model, and relates to the technical field of neuromorphological engineering, the delay neuron circuit comprises an initial segment myelin sheath structure and at least one middle segment myelin sheath structure; the voltage difference between the node a of the initial section myelin sheath structure and the ground forms the membrane potential of the section, and the voltage difference between the node b of the middle section myelin sheath structure and the ground forms the membrane potential of the section; the node a and the node b are connected through a resistor RT used for representing the resistance in the axon direction, and the nodes bi (i = 1, 2, 3,...) of the multiple middle segment myelin sheath structures are connected through the resistor RT. The delay neuron circuit can introduce flexible conduction delay through an adjustable myelin sheath structure while realizing basic discharge characteristics of biological neurons, so that a signal propagation process in a biological nervous system is reflected more truly.

The present invention disclosed herein relates to the novel in-situ process for preparation of conjugate of magnesium with acetylated aminosulfonic acid with high purity and high yield. The process comprising steps of in-situ catalytic acetylation of aminosulfonic acid followed by conjugation of magnesium in presence of base. Particularly, the invention provides the conjugate of magnesium with acetylated aminosulfonic acid which regulates the myelin basic protein (MBP) expression, thereby facilitating myelin sheath formation and maintenance. Furthermore, the present magnesium conjugate is useful in the treatment of disorders related to dysregulation of myelin basic protein (MBP) expression.

The application discloses a dual-response fluorescent probe for simultaneously imaging AD brain myelin and A beta aggregate as well as a preparation method and application thereof, and the probe structure is shown in any one of the following structures. The application prepares a series of amphiphilic fluorescent probes NQPI1-6 with pyridinium salt structure for central nervous system and peripheral nervous system myelin response, wherein the probe NQPI6 can specifically simultaneously image myelin integrity and A beta aggregation in mouse brain tissue. The probe can perform detailed three-dimensional imaging on the myelin structure rich in lipids, can be effectively combined with A beta plaque, and can generate strong red fluorescence signals. The dual-functional fluorescent probe provides a powerful chemical tool for synchronous imaging of myelin and A beta plaque, and provides a promising tool and method for studying the interaction between A beta plaque formation and demyelination in the AD progress process.

The invention relates to the technical field of neuroscience, in particular to a method for marking a new myelin sheath in a central nervous system, which comprises the following steps: constructing an ENPP6-P2A-CreERT2-T2A-CFP gene segment, and obtaining an ENPP6-CreERT2 knock-in mouse through a gene editing technology; the ENPP6-CreERT2 mouse and the mT / mG report mouse are subjected to mating, and ENPP6-CreERT is obtained; an mT / mG double transgenic mouse; carrying out tamoxifen induction treatment on the double transgenic mice in a target time period, and activating Cre recombinase; brain tissues are collected after induction, and marked middle-stage oligodendroglia cells and myelin sheath structures formed by the middle-stage oligodendroglia cells are observed through a fluorescence report system. According to the invention, the purpose of specifically marking new myelin sheath during tamoxifen induction is achieved. And a new research tool is provided for controlling new myelin sheath in a specific time period. The problems that all new myelin sheaths after induction start can be marked in an existing method, and the new myelin sheaths in the induction period cannot be specifically marked are solved.

The invention provides an application of MF-438 in preparation of drugs for treating peripheral nerve adhesion diseases, relates to the technical field of biomedicine, and aims to fill the technical blank of clinical lack of targeted small molecule drugs for treating peripheral nerve adhesion. A verification experiment also proves that the MF-438 can obviously reduce the expression of proinflammatory factors such as IL-1alpha, IL-1beta and TNF-alpha, effectively inhibit the excessive inflammatory response of a nerve adhesion part and create a stable local microenvironment for nerve repair; meanwhile, the compound can effectively protect the sciatic nerve myelin sheath structure, increase the myelin sheath thickness and maintain the myelin sheath integrity, and the nerve protection and repair effects are directly achieved; in addition, the MF-438 has good cell permeability and oral bioavailability, the administration mode is simple and convenient, the action effect is clear, and the experimental safety is good, so that the MF-438 has higher clinical transformation and industrialization potential, and a safe, efficient and clear-mechanism brand new treatment strategy is provided for peripheral nerve adhesion diseases.